HK1149710A1 - A powerful vaccine composition comprising a lipopeptide and poly i:c as an adjuvant - Google Patents

A powerful vaccine composition comprising a lipopeptide and poly i:c as an adjuvant

Info

Publication number
HK1149710A1
HK1149710A1 HK11103923.3A HK11103923A HK1149710A1 HK 1149710 A1 HK1149710 A1 HK 1149710A1 HK 11103923 A HK11103923 A HK 11103923A HK 1149710 A1 HK1149710 A1 HK 1149710A1
Authority
HK
Hong Kong
Prior art keywords
lipopeptide
adjuvant
poly
vaccine composition
powerful vaccine
Prior art date
Application number
HK11103923.3A
Other languages
English (en)
Inventor
Hong Mo Moon
Byung Cheol Ahn
Jung Sun Yum
Original Assignee
Dobeel Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dobeel Co Ltd filed Critical Dobeel Co Ltd
Publication of HK1149710A1 publication Critical patent/HK1149710A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/29Hepatitis virus
    • A61K39/292Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082Hepadnaviridae, e.g. hepatitis B virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
HK11103923.3A 2007-12-07 2011-04-19 A powerful vaccine composition comprising a lipopeptide and poly i:c as an adjuvant HK1149710A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020070126775A KR100900837B1 (ko) 2007-12-07 2007-12-07 리포펩타이드와 폴리(i:c)를 아쥬반트로 포함하는 강력한백신 조성물
PCT/KR2008/006842 WO2009072767A2 (en) 2007-12-07 2008-11-20 A powerful vaccine composition comprising a lipopeptide and poly i:c as an adjuvant

Publications (1)

Publication Number Publication Date
HK1149710A1 true HK1149710A1 (en) 2011-10-14

Family

ID=40718329

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11103923.3A HK1149710A1 (en) 2007-12-07 2011-04-19 A powerful vaccine composition comprising a lipopeptide and poly i:c as an adjuvant

Country Status (9)

Country Link
US (1) US8216595B2 (zh)
EP (1) EP2214705B1 (zh)
JP (1) JP5485165B2 (zh)
KR (1) KR100900837B1 (zh)
CN (1) CN101883585B (zh)
AU (1) AU2008332196B2 (zh)
CA (1) CA2706101C (zh)
HK (1) HK1149710A1 (zh)
WO (1) WO2009072767A2 (zh)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080299140A1 (en) * 2002-05-24 2008-12-04 The Regents Of The University Of California, Immunogenic Composition and Peptide Sequences for Prevention and Treatment of an Hsv Condition
EP1951281B1 (en) 2005-10-17 2015-04-15 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
ES2804472T3 (es) 2005-12-13 2021-02-08 Harvard College Estructuras para trasplante celular
US9265816B2 (en) 2006-04-10 2016-02-23 Sloan Kettering Institute For Cancer Research Immunogenic WT-1 peptides and methods of use thereof
WO2009002401A2 (en) 2007-06-21 2008-12-31 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
US8466259B2 (en) * 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
EP2254602B1 (en) 2008-02-13 2018-11-21 President and Fellows of Harvard College Continuous cell programming devices
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
US8287880B2 (en) 2009-06-02 2012-10-16 National Health Research Institutes Lipidated vaccine against dengue virus infection
TWI409275B (zh) 2009-06-22 2013-09-21 Nat Health Research Institutes 脂質化腫瘤相關抗原及其免疫治療的組成物及方法
US8728456B2 (en) * 2009-07-31 2014-05-20 President And Fellows Of Harvard College Programming of cells for tolerogenic therapies
US11202759B2 (en) 2010-10-06 2021-12-21 President And Fellows Of Harvard College Injectable, pore-forming hydrogels for materials-based cell therapies
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
WO2012139094A2 (en) 2011-04-08 2012-10-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of developing a vaccine using peptide-poly ic complexes
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
EP2701745B1 (en) 2011-04-28 2018-07-11 President and Fellows of Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
JP6062426B2 (ja) 2011-06-03 2017-01-18 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ インサイチュー抗原生成癌ワクチン
NL2007536C2 (en) 2011-10-05 2013-04-08 Academisch Ziekenhuis Leiden Lumc Adjuvant compound.
BR112014007927B1 (pt) 2011-10-06 2021-04-13 Immunovaccine Technologies Inc Composições de lipossoma compreendendo um adjuvante e usos das referidas composições e usos das referidas composições
US20150104413A1 (en) 2012-01-13 2015-04-16 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
ES2773895T3 (es) 2012-04-16 2020-07-15 Harvard College Composiciones de sílice mesoporosa para modular las respuestas inmunitarias
CN102949717A (zh) * 2012-07-06 2013-03-06 中国疾病预防控制中心病毒病预防控制所 一种含poly I:C佐剂的新型乙肝疫苗制剂
AU2013317805B2 (en) * 2012-09-21 2018-07-26 Pds Biotechnology Corporation Improved vaccine compositions and methods of use
KR101669142B1 (ko) 2012-10-10 2016-10-25 연세대학교 산학협력단 안약형 백신의 신규 아쥬반트
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
HUE052541T2 (hu) 2013-01-15 2021-05-28 Memorial Sloan Kettering Cancer Center Immunogén WT-1 peptidek és eljárások azok alkalmazására
KR101501583B1 (ko) * 2013-03-29 2015-03-12 주식회사 차백신연구소 리포펩티드 및 폴리(i:c)를 포함하는 아쥬반트 및 이를 이용한 개선된 제형의 백신 조성물
JP7348708B2 (ja) 2014-04-30 2023-09-21 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 組み合わせワクチン装置および癌細胞を殺滅する方法
CN104208670B (zh) * 2014-09-09 2017-07-28 韩自勤 一种治疗乙肝的药物组合物
CA3116265A1 (en) 2014-10-07 2016-04-14 Cytlimic Inc. Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell
EP3242883A4 (en) 2015-01-06 2018-10-17 ImmunoVaccine Technologies Inc. Lipid a mimics, methods of preparation, and uses thereof
US11786457B2 (en) 2015-01-30 2023-10-17 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
DK3269733T3 (da) 2015-03-09 2020-07-27 Cytlimic Inc Peptid afledt af gpc3, farmaceutisk sammensætning til behandling eller forebyggelse af cancer under anvendelse deraf, immunitetsinducer og fremgangsmåde til fremstilling af antigenpræsenterende celler
ES2844049T3 (es) 2015-04-07 2021-07-21 Cytlimic Inc Adyuvante para vacunas contra el cáncer
JP7094533B2 (ja) 2015-04-10 2022-07-04 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫細胞捕捉デバイスおよびその製造および使用方法
JP6989134B2 (ja) 2015-11-18 2022-01-05 イミューノヴァクシーン テクノロジーズ インコーポレイテッドImmunovaccine Technologies Inc. ポリi:cポリヌクレオチドアジュバント及び脂質系アジュバントを含むアジュバント系及び水を含まないワクチン組成物
CN115531609A (zh) 2016-02-06 2022-12-30 哈佛学院校长同事会 重塑造血巢以重建免疫
AU2017295704B2 (en) 2016-07-13 2023-07-13 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
US11291718B2 (en) 2016-10-11 2022-04-05 Cytlimic Inc. Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein
CN107261136B (zh) * 2017-07-31 2020-07-28 中国医学科学院医学生物学研究所 多聚磷酸钠的应用及含有多聚磷酸钠的疫苗剂
KR102098097B1 (ko) * 2017-08-16 2020-05-26 주식회사 차백신연구소 리포펩티드가 삽입된 리포좀을 유효성분으로 포함하는 백신 아쥬반트 및 이의 용도
WO2019051540A1 (en) * 2017-09-12 2019-03-21 Garvan Institute Of Medical Research METHODS OF REDUCING OR STOPPING LACTATION IN NON-HUMAN MAMMALS AND RELATED REACTIVES
CN109793891A (zh) * 2017-11-17 2019-05-24 韩震 多肽化合物在制备提高治疗性抗体疗效的佐剂中的应用与组合物及其制备方法
CN109200056A (zh) * 2018-11-20 2019-01-15 苏州系统医学研究所 聚肌胞在防治胰腺炎及其相关病症中的用途
US20230338533A1 (en) * 2020-05-15 2023-10-26 Rxcell Inc. Hypoimmunogenic Cells and Uses Thereof in Immune Responses
US20230390384A1 (en) * 2020-11-09 2023-12-07 Cha Vaccine Research Institute Co., Ltd Recombinant covid-19 vaccine composition comprising lipopeptide and poly (i:c) adjuvant, and use thereof
KR102292147B1 (ko) * 2020-11-18 2021-08-23 주식회사 차백신연구소 경구용 항바이러스제 및 리포펩타이드와 폴리(i:c) 아쥬반트를 포함한 치료백신을 유효성분으로 포함하는 만성 b형 간염의 예방 또는 치료용 약제학적 조성물, 약제학적 병용제제, 병용제 키트
CN117377486A (zh) 2021-05-24 2024-01-09 株式会社车疫苗研究所 采用包括脂肽和聚 (i∶c)的佐剂的免疫肿瘤学治疗组合物
KR102375057B1 (ko) * 2021-09-29 2022-03-17 주식회사 애스톤사이언스 Hsp90 항원성 펩타이드를 포함하는 항암용 백신 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839275A (en) 1983-12-01 1989-06-13 The Jewish Hospital Circulating antigens of dirofilaria immitis, monoclonal antibodies specific therefor and methods of preparing such antibodies and detecting such antigens
US4656251A (en) 1985-01-28 1987-04-07 Mallinckrodt, Inc. Rapid separation of Dirofilaria immitis immune complexes
ZW8893A1 (en) 1992-07-21 1994-06-01 Pitman Moore Inc Vaccines
GB9322702D0 (en) 1993-11-03 1993-12-22 Agricultural & Food Res Vaccines
AU701642B2 (en) 1994-03-25 1999-02-04 Mallinckrodt Veterinary, Inc. Vaccines against helminthic parasites
AU3911697A (en) 1996-08-09 1998-03-06 Trustees Of Dartmouth College Method of augmenting t cell-mediated immunity against (toxoplasma gondii)
EP1434859A2 (en) * 2001-07-25 2004-07-07 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
AU2003300184B8 (en) * 2002-12-30 2009-12-03 3M Innovative Properties Company Immunostimulatory combinations
GB0321615D0 (en) * 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
AU2003290460A1 (en) * 2003-12-24 2005-07-14 Leiden University Medical Center Synthetic protein as tumor-specific vaccine
DE102004049223A1 (de) * 2004-10-08 2006-04-20 Johannes-Gutenberg-Universität Mainz Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung
AU2006206973C1 (en) 2005-01-19 2012-06-28 Sumitomo Dainippon Pharma Co., Ltd. Emulsified composition for dilution and cancer vaccine composition
JP5221337B2 (ja) * 2005-03-31 2013-06-26 ライデン ユニバーシティ メディカル センター ミコバクテリア感染及び結核疾病の診断、予防及び治療のための方法及び手段
JP2008542405A (ja) * 2005-06-08 2008-11-27 ニューバイオメッド ピーアイケイエイ プライベート リミテッド ポリイノシン酸‐ポリシチジル酸に基づくアジュバント
JP4828189B2 (ja) * 2005-09-14 2011-11-30 雅美 森山 分泌型IgA及びIgG抗体誘導剤
US7438916B2 (en) 2005-10-14 2008-10-21 Virginia Tech Intellectual Properties, Inc. Therapeutic target for protozoal diseases
CA2632797A1 (en) * 2005-12-01 2007-06-07 The Provost, Fellows And Scholars Of The College Of The Holy And Undivid Ed Trinity Of Queen Elizabeth Near Dublin Compositions and methods relating to treatment of cancer and infectious diseases using toll like receptor agonists
EP1795599A1 (en) 2005-12-09 2007-06-13 Schuler, Gerold, Prof. Dr. Methods for generating antigen-specific effector T cells
KR100836745B1 (ko) 2007-01-31 2008-06-10 (주)두비엘 Hbv 백신 및 그의 제조 방법

Also Published As

Publication number Publication date
WO2009072767A2 (en) 2009-06-11
US8216595B2 (en) 2012-07-10
EP2214705A4 (en) 2011-11-30
CA2706101A1 (en) 2009-06-11
WO2009072767A3 (en) 2009-07-23
CN101883585A (zh) 2010-11-10
CN101883585B (zh) 2013-04-17
JP2011506309A (ja) 2011-03-03
US20090155308A1 (en) 2009-06-18
EP2214705B1 (en) 2014-08-20
KR100900837B1 (ko) 2009-06-04
EP2214705A2 (en) 2010-08-11
JP5485165B2 (ja) 2014-05-07
AU2008332196A1 (en) 2009-06-11
CA2706101C (en) 2014-06-03
AU2008332196B2 (en) 2011-09-15

Similar Documents

Publication Publication Date Title
HK1149710A1 (en) A powerful vaccine composition comprising a lipopeptide and poly i:c as an adjuvant
EP1988918A4 (en) ADJUVANZ AND VACCINE COMPOSITIONS
ZA200808489B (en) Nicotine-carrier vaccine formulation
ZA201203709B (en) Immunogenic compositions and methods
GB0607088D0 (en) Vaccine
HK1144787A1 (zh) 抗口蹄疫疫苗組合物及其製備和應用
IL203899A (en) Foxm1-derived peptide compounds
IL209027A0 (en) Vaccine compositions and uses thereof
GB0810869D0 (en) Vaccine adjuvant composition
EP2416801A4 (en) IMMUNOGENIC COMPOSITION AND ITS USES
EP2162460A4 (en) VACCINES AGAINST CHLAMYDIA INFECTIONS
EP2334332A4 (en) NEW COMPOSITIONS AND NEW ADJUVANTS
EP2207567A4 (en) IMMUNOGENIC FORMULATIONS
HK1138786A1 (en) Prophylactic tuberculosis vaccine
GB0823497D0 (en) Immunogenic composition and use thereof
GB0805356D0 (en) Vaccine adjuvant composition
EP2075005A4 (en) SALK VACCINE (IPV) AND AGAINST DIPHTHERIA, STRIPS AND TETANOS (DPT)
EP2252326A4 (en) VACCINE COMPOSITIONS
GB0818065D0 (en) Immunogenic peptides and uses thereof
EP2054081A4 (en) VACCINE AGAINST THE JC VIRUS
EP2337847A4 (en) ADJUVANTS FOR VACCINES
GB0617602D0 (en) Vaccine
TWI346557B (en) Adjuvant and vaccine includes the same
GB0606856D0 (en) Vaccine compositions
GB0801122D0 (en) Vaccine composition